Novel and emerging treatment options for R/R DLBCL
We provide an overview of the approved and emerging therapeutic options for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Related Articles
Assessment of risk of malignancy with application of Sydney classification for reporting of lymph node cytopathology in pediatric population: An institutional experience
Fine-needle aspiration cytology is a highly sensitive and reliable tool for the evaluation of lymphadenopathy in the pediatric population. The incorporation of the Sydney system…
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers
Treatment with AMG 193 preferentially inhibits the growth of MTAP-deleted tumors in preclinical models and demonstrates clinical activity in ongoing early phase trials.
Air pollution exposure elevates risk for blood clot hospitalization
Long-term exposure to certain air pollutants significantly increased risk for venous thromboembolism, according to results of an observational study.Adults who had higher exposure to fine…
ESMO Announces the Launch of Its Globalised Patient Advocates Working Group
Bringing together cancer patient advocates from around the world will create a bridge between diverse experiences and perspectives
Tumour hypoxia in driving genomic instability and tumour evolution
Nature Reviews Cancer – In this Review, Suvac et al. discuss how intratumoural hypoxia is a driving force in tumour evolution, alongside driver gene mutations,…
Insurers, providers team up to save exchange subsidies
Keep Americans Covered, a health industry coalition fronted by a former GOP operative, is the vanguard in the fight to preserve enhanced exchange subsidies.
From the Bench, Winter 2025: Urine-powered Nanomotors, Organoid Muffin Tins, and MoreÂ
This quarterly series on creative approaches to cancer research includes urine-powered nanomotors, unique molds to grow organoids, and more.
Second-Line Fedratinib Produces Early Platelet Count Improvements in Myelofibrosis
Fedratinib showed early improvements in platelet count in patients with myelofibrosis.
AI Model Learns Generalized ‘Language’ of Regulatory Genomics, Predicts Cellular Stories
The model, called EpiBERT, was inspired by BERT, a deep learning model designed to understand and generate human-like language.